Remdesivir as a potential antiviral agent for COVID-19: A literature review
This novel coronavirus infection was reported in Wuhan, China, in December 2019. It was declared a global pandemic by the WHO in March 2020. The coronavirus is an enveloped positive sense, single-stranded RNA virus. The symptoms of coronavirus disease 2019 (COVID-19) infection ranges from asymptomat...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2020-01-01
|
| Series: | Current Medicine Research and Practice |
| Subjects: | |
| Online Access: | http://www.cmrpjournal.org/article.asp?issn=2352-0817;year=2020;volume=10;issue=5;spage=238;epage=240;aulast=Josey |
| Summary: | This novel coronavirus infection was reported in Wuhan, China, in December 2019. It was declared a global pandemic by the WHO in March 2020. The coronavirus is an enveloped positive sense, single-stranded RNA virus. The symptoms of coronavirus disease 2019 (COVID-19) infection ranges from asymptomatic disease to fatal pneumonia. Remdesivir is a broad-spectrum antiviral agent. It is a nucleotide analogue, which targets viral replication. Remdesivir has demonstrated antiviral activity againstin vitro andin vivo animal models against multiple viruses such as Ebola, Middle East respiratory syndrome, and severe acute respiratory syndrome. A literature search was conducted up to 1 July 2020 using search Google Scholar, PubMed, and ClinicalTrials.gov to identify the potential of remdesivir in COVID-19 infection. Remdesivir has demonstrated clinical efficacy in the treatment of COVID-19. On 1 May 2020, the US Food and Drug Administration issued an emergency use authorisation to both suspected and confirmed cases of COVID-19. The use of remdesivir in COVID-19 has shown to be effective in reducing the clinical signs and symptoms. Further studies are required to study effectiveness as well as safety. |
|---|---|
| ISSN: | 2352-0817 2352-0825 |